Serum CGRP in migraine patients using erenumab as preventive treatment
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Serum CGRP in migraine patients using erenumab as preventive treatment
Authors
Keywords
-
Journal
JOURNAL OF HEADACHE AND PAIN
Volume 23, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-09-12
DOI
10.1186/s10194-022-01483-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CGRP-mediated trigeminovascular reactivity in migraine patients treated with erenumab
- (2022) Simone de Vries Lentsch et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Changing levels of sex hormones and calcitonin gene-related peptide (CGRP) during a woman’s life: Implications for the efficacy and safety of novel antimigraine medications
- (2021) Simone de Vries Lentsch et al. MATURITAS
- E-diary use in clinical headache practice: A prospective observational study
- (2021) Daphne S van Casteren et al. CEPHALALGIA
- Excitatory Effects of Calcitonin Gene-Related Peptide (CGRP) on Superficial Sp5C Neurons in Mouse Medullary Slices
- (2021) Fang Zheng et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Treatment with the monoclonal calcitonin gene‐related peptide receptor antibody erenumab: A real‐life study
- (2021) Simone de Vries Lentsch et al. EUROPEAN JOURNAL OF NEUROLOGY
- Comparing Perimenstrual and Nonperimenstrual Migraine Attacks Using an e-Diary
- (2021) Daphne S. van Casteren et al. NEUROLOGY
- Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study
- (2021) Antoinette MaassenVanDenBrink et al. JOURNAL OF HEADACHE AND PAIN
- One-year sustained efficacy of erenumab in episodic migraine
- (2020) Peter J. Goadsby et al. NEUROLOGY
- A proof-of-concept study on CGRP plasma levels of migraineurs during a 6-month treatment with ERENUMAB
- (2020) Giuseppe Tringali et al. JOURNAL OF HEADACHE AND PAIN
- Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial
- (2020) Wim M Mulleners et al. LANCET NEUROLOGY
- Anti-CGRP and anti-CGRP receptor monoclonal antibodies as antimigraine agents. Potential differences in safety profile postulated on a pathophysiological basis
- (2019) Giuseppe Tringali et al. PEPTIDES
- Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
- (2019) Michel D Ferrari et al. LANCET
- High‐dose phenylephrine increases meningeal blood flow through TRPV1 receptor activation and release of calcitonin gene‐related peptide
- (2019) Mária Dux et al. EUROPEAN JOURNAL OF PAIN
- Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial
- (2018) Vladimir Skljarevski et al. CEPHALALGIA
- Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study
- (2018) Messoud Ashina et al. CEPHALALGIA
- ARISE: A Phase 3 randomized trial of erenumab for episodic migraine
- (2018) David W Dodick et al. CEPHALALGIA
- Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
- (2018) CEPHALALGIA
- Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine
- (2018) David W. Dodick et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study
- (2018) Uwe Reuter et al. LANCET
- Calcitonin Gene-Related Peptide: Physiology and Pathophysiology
- (2014) F. A. Russell et al. PHYSIOLOGICAL REVIEWS
- Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine
- (2013) E. Cernuda-Morollon et al. NEUROLOGY
- Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura
- (2010) Jakob Møller Hansen et al. CEPHALALGIA
- Calcitonin gene-related peptide (CGRP) levels during glyceryl trinitrate (GTN)-induced headache in healthy volunteers
- (2009) C Kruuse et al. CEPHALALGIA
- Early and Late Contributions of Glutamate and CGRP to Mechanical Sensitization by Endothelin-1
- (2009) Alla Khodorova et al. JOURNAL OF PAIN
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started